WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016085904) ANTI-MUTATED KRAS T CELL RECEPTORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/085904    International Application No.:    PCT/US2015/062269
Publication Date: 02.06.2016 International Filing Date: 24.11.2015
IPC:
A61K 45/06 (2006.01), C07K 14/82 (2006.01), A61K 39/00 (2006.01)
Applicants: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard, Suite 325 MSC 7660 Bethesda, Maryland 20892-7660 (US)
Inventors: WANG, Qiong J.; (US).
YU, Zhiya; (US).
YANG, James C.; (US)
Agent: LAWLEY, Stephanie M.; (US)
Priority Data:
62/084,654 26.11.2014 US
62/171,321 05.06.2015 US
Title (EN) ANTI-MUTATED KRAS T CELL RECEPTORS
(FR) RÉCEPTEURS DE LYMPHOCYTES T KRAS ANTI-MUTATION
Abstract: front page image
(EN)Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for an HLA-A11-restricted epitope of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) (KRAS7-16), Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS), or Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
(FR)L'invention concerne un récepteur de lymphocyte T (TCR) isolé ou purifié ayant une spécificité antigénique pour un épitope limité en HLA-A11 d'un homologue d'oncogène viral de sarcome de rat de Kirsten (KRAS) muté (KRAS7-16), d'homologue d'oncogène viral RAS de neuroblastome (V-Ras) (NRAS), ou d'homologue d'oncogène viral de sarcome de rat de Harvey (HRAS). L'invention concerne également des protéines et des polypeptides associés, ainsi que des acides nucléiques, des vecteurs d'expression recombinants, des cellules hôtes, des populations de cellules et des compositions pharmaceutiques associés. La présente invention concerne également des procédés pour détecter la présence d'un cancer chez un mammifère, et des procédés de traitement ou de prévention d'un cancer chez un mammifère.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)